You are here: Industry Insights > ADC

News List

Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC prnasia
April 19, 2021
Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines announced that the companies ...
Sterling Pharma Solutions Acquires ADC Biotechnology contractpharma
April 08, 2021
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has acquired ADC Biotechnology, a UK-based bioconjugation development services business specializing in antibody drug conjugates (ADCs).
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors americanpharmaceuticalreview
April 07, 2021
Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with ...
Eisai Begins Construction of New Injection/Research Building contractpharma
March 23, 2021
Eisai Co., Ltd., as part of a strategic investment, began construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" (EMITS) at the Kawashima Industrial Park in Gifu Prefecture, Japan.
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients prnasia
February 25, 2021
Genome & Company today announced having entered into a research collaboration for the discovery of innovative cancer therapies in the expanding antibody-drug conjugates (ADC) class.
Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage prnasia
February 01, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has ...
BrickBio Inks ADC Co-Development Deal contractpharma
January 07, 2021
BrickBio, a company specializing in site-specific bioconjugation for improved therapeutics, has signed an agreement with a large pharmaceutical company to co-develop a therapeutic antibody drug conjugate (ADC).
Lantern Pharma Launches ADC Program contractpharma
January 05, 2021
Lantern Pharma, a clinical-stage biopharma company using its RADR artificial intelligence platform to advance cancer drug development, is launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential ...
PPF Group Sells Sake in NBE-Therapeutics to Boehringer Ingelheim americanpharmaceuticalreview
December 31, 2020
PPF Group has announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) ...
Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction contractpharma
December 11, 2020
PPF Group, an international investment group, has signed an agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page